Literature DB >> 15007714

Interstitial nephritis from mesalazine: case report and literature review.

Lois J Arend1, James E Springate.   

Abstract

We report a new case of biopsy-confirmed mesalazine-induced interstitial nephritis in an 18-year-old male with ulcerative colitis. His renal function improved with drug discontinuation and corticosteroid treatment. An English literature review revealed an additional 22 cases of this complication that, taken together, showed (1) a male predominance, (2) an absence of specific symptoms or findings on urinalysis, (3) a 61% frequency of residual chronic renal insufficiency with 13% of patients developing end-stage renal disease, and (4) an apparent favorable response to steroid therapy. We conclude that patients receiving 5-aminosalicylates should be routinely monitored with serum creatinine measurements to prevent this uncommon but potentially serious adverse drug reaction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15007714     DOI: 10.1007/s00467-004-1411-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  25 in total

Review 1.  Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.

Authors:  G Corrigan; P E Stevens
Journal:  Aliment Pharmacol Ther       Date:  2000-01       Impact factor: 8.171

2.  Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease.

Authors:  J Calviño; R Romero; E Pintos; E Losada; D Novoa; D Güimil; J Mardaras; D Sanchez-Guisande
Journal:  Clin Nephrol       Date:  1998-04       Impact factor: 0.975

3.  Renal dysfunction and the treatment of inflammatory bowel disease (IBD): a case for monitoring.

Authors:  G Howard; K L Lynn
Journal:  Aust N Z J Med       Date:  1998-06

4.  Nephrotoxicity associated with olsalazine.

Authors:  G M Wilcox; J R Reynolds; E G Galvanek
Journal:  Am J Med       Date:  1996-02       Impact factor: 4.965

Review 5.  5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?

Authors:  M E De Broe; J C Stolear; E J Nouwen; M M Elseviers
Journal:  Nephrol Dial Transplant       Date:  1997-09       Impact factor: 5.992

6.  Mesalazine-associated interstitial nephritis.

Authors:  M J World; P E Stevens; M A Ashton; D J Rainford
Journal:  Nephrol Dial Transplant       Date:  1996-04       Impact factor: 5.992

7.  5-Aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease.

Authors:  J Hämling; A Raedler; U Helmchen; S Schreiber
Journal:  Digestion       Date:  1997       Impact factor: 3.216

8.  Nephrotoxic lesions from 5-aminosalicylic Acid.

Authors:  I C Calder; C C Funder; C R Green; K N Ham; J D Tange
Journal:  Br Med J       Date:  1972-01-15

9.  Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.

Authors:  Niels Erik Frandsen; Søren Saugmann; Niels Marcussen
Journal:  Nephron       Date:  2002-09       Impact factor: 2.847

10.  Tests of renal function in patients with quiescent colitis: effects of drug treatment.

Authors:  S A Riley; D R Lloyd; V Mani
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

View more
  19 in total

1.  Mesalazine-induced interstitial nephritis in a patient with ulcerative colitis.

Authors:  Emmanuel Cruz Gorospe; Cadman L Leggett
Journal:  BMJ Case Rep       Date:  2012-02-25

Review 2.  Drug-induced acute interstitial nephritis.

Authors:  Mark A Perazella; Glen S Markowitz
Journal:  Nat Rev Nephrol       Date:  2010-06-01       Impact factor: 28.314

3.  Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event.

Authors:  Pedro Magalhães-Costa; Leopoldo Matos; Cristina Chagas
Journal:  BMJ Case Rep       Date:  2015-05-02

Review 4.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors:  Yongjun Wang; Claire E Parker; Tania Bhanji; Brian G Feagan; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-04-21

5.  Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatment.

Authors:  N Siddique; C Farmer; A F Muller
Journal:  Frontline Gastroenterol       Date:  2014-06-04

6.  Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease.

Authors:  Nuray Uslu; Hulya Demir; Inci Nur Saltik-Temizel; Rezan Topaloğlu; Figen Gürakan; Aysel Yüce
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

Review 7.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 8.  Curcumin for maintenance of remission in ulcerative colitis.

Authors:  Sushil Kumar; Vineet Ahuja; Mari Jeeva Sankar; Atul Kumar; Alan C Moss
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

9.  Renal effects of long-term treatment with 5-aminosalicylic acid.

Authors:  H Patel; A Barr; K N Jeejeebhoy
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

10.  The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease.

Authors:  Josephine M Ambruzs; Patrick D Walker; Christopher P Larsen
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.